This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. **(Currently Amended)** A pharmaceutical ~~Pharmaceutical~~ composition obtainable ~~that can be obtained~~ by mixing at least one active ingredient comprising a 17-β-estradiol or ethinylestradiol with at least one extrusion additive from a polyalcohol ~~the group of polyalcohols~~ esterified with a fatty acid ~~acids~~ wherein the extrusion additive comprises a sugar fatty acid ester, a polyethylene glycol fatty acid ester or a glycerol fatty acid ester, and an adjuvant comprising polyvinylpyrrolidone, polyethylene glycol, vinylpyrrolidonevinyl acetate copolymer or a mixture thereof and joint melt extruding ~~extrusion~~.

2. **(Canceled)**

3. **(Canceled)**

4. **(Currently Amended)** A pharmaceutical composition ~~Pharmaceutical compositions~~ according to claim 1, wherein the fatty acid has ~~acids have~~ 1 to 31 carbon atoms and are unbranched and/or branched and/or saturated and/or unsaturated.

5. **(Canceled)**

6. **(Currently Amended)** A pharmaceutical ~~Pharmaceutical~~ composition according to claim ~~Claim~~ 1, wherein the melt extrusion is carried out without additional heat

input.

7. **(Currently Amended)** A pharmaceutical ~~Pharmaceutical~~ composition according to claim 1 wherein the extrusion additive is saccharose monopalmitate and the composition is obtainable ~~that can be obtained~~ by mixing 17-β-estradiol, polyvinylpyrrolidone and saccharose monopalmitate and joint melt extruding ~~extrusion~~ at 60°C.

8. **(Currently Amended)** A pharmaceutical ~~Pharmaceutical~~ composition according to claim 1 wherein the extrusion additive is glycerol tribehenate and the composition is obtainable ~~that can be obtained~~ by mixing 17-β-estradiol, polyvinylpyrrolidone and glycerol tribehenate and joint melt extruding ~~extrusion~~ at 60°C.

9. **(Currently Amended)** A pharmaceutical ~~Pharmaceutical~~ composition according to claim 1 wherein the extrusion additive is saccharose monopalmitate and the composition is obtainable ~~that can be obtained~~ by mixing ethinylestradiol, polyvinyl-pyrrolidone and saccharose monopalmitate and joint melt extruding ~~extrusion~~ at 60°C.

10. **(Currently Amended)** A process ~~Process~~ for the production of a pharmaceutical composition comprising joint melt extruding a mixture comprising ~~compositions in which~~ at least one active ingredient of 17-β-estradiol or ethinylestradiol ~~is mixed~~ with at least one extrusion additive ~~from the group~~ of a polyalcohol ~~polyalcohols~~ esterified with a fatty acid ~~acids, and the mixture that is thus obtained is then subjected to a joint melt extrusion~~.

11. **(Currently Amended)** A process ~~Process~~ according to claim 10, wherein the melt extrusion is carried out without heat input.

12. **(Currently Amended)** A process ~~Process~~ according to claim 10, further comprising grinding ~~wherein in addition,~~ the extruded mixture ~~is ground~~ and ~~further processed~~ processing into a pharmaceutical agent ~~agents~~ with a ~~additional~~ pharmaceutically compatible adjuvant or additive ~~adjuvants and additives~~.

13. **(Currently Amended)** A pharmaceutical agent comprising ~~Pharmaceutical agents that contain~~ a pharmaceutical composition according to claim 1 and a ~~together with additional~~ pharmaceutically compatible adjuvant or additive ~~adjuvants and additives~~.

14. **(Canceled)**

Please add the following new claims:

--15. **(New)** A process according to claim 11, further comprising grinding the extruded mixture and processing into a pharmaceutical agent with a pharmaceutically compatible adjuvant or additive.

16. **(New)** A pharmaceutical composition according to claim 1, wherein the composition comprises a low-dose amount of the at least one active ingredient.

17. (New) A pharmaceutical composition according to claim 1, wherein the composition comprises 0.025% of at least one active ingredient relative to a single dose.

18. (New) A pharmaceutical composition according to claim 1, wherein the extrusion additive is from polyalcohols esterified with fatty acids.

19. (New) A pharmaceutical composition according to claim 1, wherein the extrusion additive consists of a sugar fatty acid ester, a polyethylene glycol fatty acid ester or a glycerol fatty acid ester, the at least one active ingredient consists of 17-β-estradiol or ethinylestradiol, and the adjuvant consists of polyvinylpyrrolidone, polyethylene glycol, vinylpyrrolidonevinyl acetate copolymer, or a mixture thereof.

20. (New) A pharmaceutical composition obtainable by extruding a mixture comprising 17-β-estradiol or ethinylestradiol and a sugar fatty acid ester, a polyethylene glycol fatty acid ester or a glycerol fatty acid ester.

21. (New) A process according to claim 10, wherein the extrusion additive is from polyalcohols esterified with fatty acids.

22. (New) A pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is a solid dispersion.

23. (New) A mixture comprising 17-β-estradiol or ethinylestradiol and a sugar fatty acid ester, a polyethylene glycol fatty acid ester or a glycerol fatty acid ester.--